Arylpyrazole derivatives as anti-platelet agents
CA 2022183 C · Owner: Bristol-Myers Squibb Company · Inventors: Meanwell, Nicholas Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Compounds of the formula, (see above formula) wherein, R1 and R2 each are independently hydrogen or phenyl provided that R1 and R2 may not both be hydrogen;, m is an integer ~rom 3 to 9; n is an integer from 0 to 3 and the sum of m+n is an integer from 5 to 12;, Z is O S, SO, SO2, -CH=CH- or a direct bond;, A R3 is hydrogen or C1-6 alkyl; and, R4 is hydrogen C1-4 alkyl or methylsulfonyl;, and pharmaceutically acceptable salts or hydrates thereof are novel inhibitors of adenosine diphosphate and collagen-induced aggregation of human platelet-rich plasma and are particularly useful as inhibitors of mammalian blood platelet aggregation.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 27, 1990 and granted July 18, 2000. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 27, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 27, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.